MedPath

Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men

Phase 3
Completed
Conditions
Osteoporosis
Registration Number
NCT00097825
Lead Sponsor
Novartis Pharmaceuticals
Brief Summary

The goal of this study is to determine the effectiveness and safety of an annual intravenous treatment of zoledronic acid for the treatment of osteoporosis in men. All patients will receive calcium and vitamin D supplements.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
288
Inclusion Criteria
  • Male, 25-85 years old
Exclusion Criteria
  • Current users of bisphosphonates such as Aredia® (pamidronate), Didronel® (etidronate), Fosamax® (alendronate), Actonel ® (residronate), Skelid® (tiludronate)
  • History of severe liver, kidney or eye disease

Other protocol-defined inclusion/exclusion criteria may apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
To compare % change in Lumbar Spine BMD from Baseline to Month 24 in ZOL (annual i.v. infusion) vs Alendronate (weekly oral) osteoporotic male populations
Secondary Outcome Measures
NameTimeMethod
To compare % change in Lumbar Spine BMD from Baseline to Months 6 and 12 in ZOL (annual i.v. infusion) vs Alendronate (weekly oral) osteoporotic male populations
To compare % change in BMD at the Total Hip, Femoral Neck, Trochanter and Total Body, from Baseline to Months 6, 12 and 24 in ZOL (annual i.v. infusion) vs Alendronate (weekly oral) osteoporotic male populations
To compare Biomarkers of bone turnover in the annual Zol i.v. and weekly alendronate populations at all study timepoints, relative to Baseline

Trial Locations

Locations (25)

St. Joseph Hospital

🇺🇸

Bangor, Maine, United States

Osteoporosis and Clinical Trials Center

🇺🇸

Hagerstown, Maryland, United States

UC Bone Health and Osteoporosis Center

🇺🇸

Cincinnati, Ohio, United States

Garvan Institute of Medical Research

🇦🇺

Sydney, New South Wales, Australia

Keogh Institute for Medical Research

🇦🇺

Nedlands, Western Australia, Australia

Diablo Clinical Research

🇺🇸

Walnut Creek, California, United States

United Osteoporosis Center

🇺🇸

Gainesville, Georgia, United States

Colorado Center for Bone Research

🇺🇸

Lakewood, Colorado, United States

Repatriation General Hospital

🇦🇺

Daw Park, South Australia, Australia

Clinical Research Center

🇨🇦

Vancouver, British Columbia, Canada

Mercy Arthritis and Osteoporosis Center

🇺🇸

Des Moines, Iowa, United States

Catalina Pointe Clinical Research Inc.

🇺🇸

Tucson, Arizona, United States

Oregon Health Sciences University

🇺🇸

Portland, Oregon, United States

Northwestern Center for Clinical Research

🇺🇸

Chicago, Illinois, United States

New Mexico Clinical Research and Osteoporosis Center

🇺🇸

Albuquerque, New Mexico, United States

Hampton Roads Center for Clinical Research

🇺🇸

Norfolk, Virginia, United States

Helen Hayes Hospital

🇺🇸

West Haverstraw, New York, United States

McGuire VA Medical Center

🇺🇸

Richmond, Virginia, United States

Royal Victoria Hospital

🇨🇦

Montreal, Quebec, Canada

Charlton Medical Building

🇨🇦

Hamilton, Ontario, Canada

QEII HealthSciences Center

🇨🇦

Halifax, Nova Scotia, Canada

Groupe de Recherche en Rhumatologie et Maladies Osseuses

🇨🇦

Sainte-Foy, Quebec, Canada

Centre De Recherche Clinique De Laval

🇨🇦

Laval, Quebec, Canada

Saskatoon Osteoporosis Center

🇨🇦

Saskatoon, Saskatchewan, Canada

Radiant Research

🇺🇸

Wyomissing, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath